Ethyl Pyruvate Induces Tolerogenic Dendritic Cells.
2019
Autori:
Nikolovski, NedaMansilla, María José
Jevtić, Bojan
Navarro-Barriuso, Juan
Saksida, Tamara
Martínez-Cáceres, Eva M.
Miljković, Đorđe
Tip dokumenta:
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt:
Dendritic cells (DC) are professional antigen presenting cells that have a key role in shaping the immune response. Tolerogenic DC (tolDC) have immuno-regulatory properties and they are a promising prospective therapy for multiple sclerosis and other autoimmune diseases. Ethyl pyruvate (EP) is a redox analog of dimethyl fumarate (Tecfidera), a drug for multiple sclerosis treatment. We have recently shown that EP ameliorates experimental autoimmune encephalomyelitis, a multiple sclerosis murine model. Here, we expanded our study to its tolerogenic effects on DC. Phenotypic analysis has shown that DC obtained from mice or humans reduce expression of molecules required for T cell activation such as CD86, CD83, and HLA-DR under the influence of EP, while CD11c expression and viability of DC are not affected. Furthermore, EP-treated DC restrain proliferation and modulate cytokine production of allogeneic lymphocytes. These results demonstrate that EP has the ability to direct DC toward tolDC.
Ključne reči:
Autoimmunity; Dendritic cells; Ethyl pyruvate; Immune-regulation; TolerogenicityIzvor:
Frontiers in Immunology, 2019, 10, 157-Finansiranje / projekti:
- Ćelijski i molekulski mehanizmi oporavka pacova od eksperimentalnog autoimunskog encefalomijelitisa (RS-MESTD-Basic Research (BR or ON)-173035)
- Molekularni mehanizmi fiziološke i farmakološke kontrole inflamacije i kancera (RS-MESTD-Basic Research (BR or ON)-173013)
- Plan Nacional de I+D+I (PI14/01175), (PI17/01521)
- ISCIII-Subdireccion General de Evaluacion
- Fondo Europeo de Desarrollo Regional (FEDER)
- Cost Action (BM1305)
DOI: 10.3389/fimmu.2019.00157
PubMed: 30792716
WoS: 000458067300001
Scopus: 2-s2.0-85061993185
URI
https://www.frontiersin.org/article/10.3389/fimmu.2019.00157/fullhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6374627
https://radar.ibiss.bg.ac.rs/handle/123456789/3280